Drug Resistance in Cancer Cells / Edition 1

by Susan E. Bates, Kapil Mehta, Zahid H. Siddik

Overview

It was estimated that in 2008, 1,437,180 patients would receive a new cancer diagnosisand 565,650individualswould die of cancer (Jemal et al. 2008).Since the vast majority of patients dying of cancer will have had anticancer therapy, both c- ventional chemotherapy and novel targeted therapy, it can be concluded that these patients are dying with drug resistant cancer. The term multidrug resistance is also apt – in that these patients die after having undergone multiple rounds of different and structurally unrelated cancer therapies. However, for some, the concept of m- tidrug resistance is a worn out idea, stemming from disappointment with the drug resistance reversal strategies that were carried out in the 1990s using pump inhibitors to block drug resistance mediated by P-glycoprotein, product of the MDR-1 gene. However, if one takes the larger definition – multidrug resistance as simultaneous resistance to multiple structurally unrelated anticancer therapies – its existence c- not be denied. The purpose of this book is to explore new concepts related to drug resistance in cancer, including resistance to the new molecularly targeted agents. Perhaps new terminology is needed for resistance that occurs following therapy with the targeted agents: Novel Targeted Agent Resistance (NTR). Alternatively, we can return to the original definition of multidrug resistance as simply the res- tance to multipleagents that occurs in the course of normalcancer progression.This resistance is likely to be mediated by many factors.

Product Details

ISBN-13:	9781441927941
Publisher:	Springer New York
Publication date:	10/29/2010
Edition description:	Softcover reprint of hardcover 1st ed. 2009
Pages:	363
Product dimensions:	6.10(w) x 9.25(h) x 0.03(d)

Table of Contents

Chapter 1: Drug resistance in cancer cells: a historical perspective (Macus T. Kuo, Houston, TX) or Victor Ling (Toronto, Canada) Chapter 2: Metastasis and drug resistance (Kapil Mehta, Houston, TX) or (Isiah Fidler, Houston, TX) Chapter 3: Apoptosis/autophagy and drug resistance (R.S. Krebel, Ontario, Canada) or (Yasuko Kondo, Houston, TX) Chapter 4: Cytokines and drug resistance (Livio Mallucci, London, UK) Chapter 5: Tissue transglutaminase and drug resistance (KapilMehta, Houston, TX) Chapter 6: Integrin signaling and drug resistance (David Cheresh, San Diego, CA) Chapter 7: Oxidative stress and drug resistance Boldogh, Istvan, UTMB, Galveston, TX) Chapter 8: NF-k B and drug resistance (Bharat B. Aggarwal, Houston, TX) Chapter 9: p53 and chemoresistance (Zahid Siddik, Houston, TX) Chapter 10: Resistance to differentiation therapy (Bulent Ozoplat, Houston, TX) Chapter 11: Assessment of cancer drug resistance by nuclear imaging (Sunil Krishnan, Houston, TX) Chapter 12: Overcoming drug resistance by phyhemicals (Bharat B. Aggarwal. Houston, TX) or (Marion M Chan, Philadelphia, USA)